1.
Eric Van Den Neste, Marc André, Thomas Gastinne, Aspasia Stamatoullas, Corinne Haioun, Amine Belhabri, Oumedaly Reman, Olivier Casasnovas, Hervé Ghesquieres, Gregor Verhoef, Marie-José Claessen, Hélène A. Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, Ioanna-Andrea Stoian, Anne S. Cottereau, Sarah Bailly, Laurent Knoops, Franck Morschhauser. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. haematol [Internet]. 2018May1 [cited 2023Jan.31];103(5):840-8. Available from: https://haematologica.org/article/view/8454